An intronic haplotype in α galactosidase A is associated with reduced mRNA expression in males with cryptogenic stroke

Gene

Volumn 549, Issue 2, 2014, Pages 275-279

  Zeevi, David A ^a   Hakam Spector, Elinor ^a   Herskovitz, Yair ^a   Beeri, Rachel ^a   Elstein, Deborah ^a   Altarescu, Gheona ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Early onset stroke; Enzyme replacement therapy; Fabry disease; Intronic variants; X linked recessive disorder; galactosidase A

Indexed keywords

ALPHA GALACTOSIDASE; GENOMIC DNA; MESSENGER RNA;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; ISRAEL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; X CHROMOSOME INACTIVATION;

EARLY-ONSET STROKE; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; INTRONIC VARIANTS; X-LINKED RECESSIVE DISORDER; Α GALACTOSIDASE A;

ADULT; AGED; ALPHA-GALACTOSIDASE; DOWN-REGULATION; FABRY DISEASE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTRONS; MALE; MIDDLE AGED; RNA, MESSENGER; SEX FACTORS; STROKE;

EID: 84906069850     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.08.004     Document Type: Article

References (43)

1. Anderson W. A case of angiokeratoma. Br. J. Dermatol. 1898, 18:113-117.
2. Bird A.P. CpG-rich islands and the function of DNA methylation. Nature 1986, 321(6067):209-213.
3. Blaydon D., Hill J., Winchester B. Fabry disease: 20 novel GLA mutations in 35 families. Hum. Mutat. 2001, 18(5):459.
4. Bosnakovski D., Xu Z., Gang E.J., Galindo C.L., Liu M., Simsek T., Garner H.R., Agha-Mohammadi S., Tassin A., Coppée F., Belayew A., Perlingeiro R.R., Kyba M. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J. 2008, 27(20):2766-2779.
5. Davies J.P., Winchester B.G., Malcolm S. Sequence variations in the first exon of α-galactosidase A. Med. Genet. 1993, 30(8):658-663.
6. Deaton A.M., Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011, 25(10):1010-1022.
7. Desnick R.J., Brady R., Barranger J., Collins A.J., Germain D.P., Goldman M., Grabowski G., Packman S., Wilcox W.R. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 2003, 138(4):338-346.
8. Dobrovolny R., Dvorakova L., Ledvinova J., Magage S., Bultas J., Lubanda J.C., Elleder M., Karetova D., Pavlikova M., Hrebicek M. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J. Mol. Med. 2005, 83(8):647-654.
9. Elstein D., Schachamorov E., Beeri R., Altarescu G. X-inactivation in Fabry disease. Gene 2012, 505(2):266-268.
10. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., Brodie S., Stacy C.B., Mehta D., Parsons R., Norton K., O'Callaghan M., Desnick R.J. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 2001, 68(3):711-722.
11. Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch. Dermatol. Syph. 1898, 43:187-200.
12. Filoni C., Caciotti A., Carraresi L., Donati M.A., Mignani R., Parini R., Filocamo M., Soliani F., Simi L., Guerrini R., Zammarchi E., Morrone A. Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients' fibroblasts results in Fabry disease. Eur. J. Hum. Genet. 2008, 16(11):1311-1317.
13. Gal A. Molecular genetics of Fabry disease and genotype-phenotype correlation. Fabry Disease 2010, 3-19. Springer, Heidelberg. D. Elstein, G. Altarescu, M. Beck (Eds.).
14. Germain D.P., Poenaru L. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. Biochem. Biophys. Res. Commun. 1999, 257(3):708-713.
15. Ishii S., Nakao S., Minamikawa-Tachino R., Desnick R.J., Fan J.Q. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am. J. Hum. Genet. 2002, 70(4):994-1002.
16. Lemmers R.J., de Kievit P., Sandkuijl L., Padberg G.W., van Ommen G.J., Frants R.R., van der Maarel S.M. Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. Nat. Genet. 2002, 32(2):235-236.
17. Lemmers R.J., Wohlgemuth M., van der Gaag K.J., van der Vliet P.J., van Teijlingen C.M., de Knijff P., Padberg G.W., Frants R.R., van der Maarel S.M. Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. 2007, 81(5):884-894.
18. Lemmers R.J., van der Vliet P.J., Klooster R., Sacconi S., Camaño P., Dauwerse J.G., Snider L., Straasheijm K.R., van Ommen G.J., Padberg G.W., Miller D.G., Tapscott S.J., Tawil R., Frants R.R., van der Maarel S.M. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010, 329(5999):1650-1653.
19. Lemmers R.J., Tawil R., Petek L.M., Balog J., Block G.J., Santen G.W., Amell A.M., van der Vliet P.J., Almomani R., Straasheijm K.R., Krom Y.D., Klooster R., Sun Y., den Dunnen J.T., Helmer Q., Donlin-Smith C.M., Padberg G.W., van Engelen B.G., de Greef J.C., Aartsma-Rus A.M., Frants R.R., de Visser M., Desnuelle C., Sacconi S., Filippova G.N., Bakker B., Bamshad M.J., Tapscott S.J., Miller D.G., van der Maarel S.M. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat. Genet. 2012, 44(12):1370-1374.
20. Lindsay S., Bird A.P. Use of restriction enzymes to detect potential gene sequences in mammalian DNA. Nature 1987, 327(6120):336-338.
21. MacDermot K.D., Holmes A., Miners A.H. Anderson Fabry disease clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet. 2001, 38:750-760.
22. MacDermot K.D., Holmes A., Miners A.H. Anderson Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate female carriers. J. Med. Genet. 2001, 38:769-775.
23. Maier E.M., Osterrieder S., Whybra C., Ries M., Gal A., Beck M., Roscher A.A., Muntau A.C. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr. Suppl. 2006, 95(451):30-38.
24. Matsumura T., Osaka H., Sugiyama N., Kawanishi C., Maruyama Y., Suzuki K., Onishi H., Yamada Y., Morita M., Aoki M., Kosaka K. Novel acceptor splice site mutation in the invariant AG of intron 6 of alpha-galactosidase A gene, causing Fabry disease. Mutations in brief no. 146. Online. Hum. Mutat. 1998, 11(6):483.
25. Mehta A., Ricci R., Widmer U., Dehout F., Garcia de Lorenzo A., Kampmann C., Linhart A., Sunder-Plassmann G., Ries M., Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest. 2004, 34:236-242.
26. Oliveira J.P., Ferreira S., Reguenga C., Carvalho F., Mansson J.E. The g.1170C>Tpolymorphism of the 5' untranslated region of the human alphagalactosidase gene is associated with decreased enzyme expression-evidence from a family study. J. Inherit. Metab. Dis. 2008, 31(Suppl. 2):405-413.
27. Pisani A., Imbriaco M., Zizzo C., Albeggiani G., Colomba P., Alessandro R., Iemolo F., Duro G. A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report. BMC Cardiovasc. Disord. 2012, 12:39.
28. Rodríguez-Marí A., Coll M.J., Chabás A. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum. Mutat. 2003, 22(3):258.
29. Rombach S.M., Smid B.E., Bouwman M.G., Linthorst G.E., Dijkgraaf M.G., Hollak C.E. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J. Rare Dis. 2013, 8:47.
30. Sacconi S., Lemmers R.J., Balog J., van der Vliet P.J., Lahaut P., van Nieuwenhuizen M.P., Straasheijm K.R., Debipersad R.D., Vos-Versteeg M., Salviati L., Casarin A., Pegoraro E., Tawil R., Bakker E., Tapscott S.J., Desnuelle C., van der Maarel S.M. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am. J. Hum. Genet. 2013, 93(4):744-751.
31. Sakuraba H., Eng C.M., Desnick R.J., Bishop D.F. Invariant exon skipping in the human alpha-galactosidase A pre-mRNA: Ag+1 to t substitution in a 5'-splice site causing Fabry disease. Genomics 1992, 12(4):643-650.
32. Schäfer E., Baron K., Widmer U., Deegan P., Neumann H.P., Sunder-Plassmann G., Johansson J.O., Whybra C., Ries M., Pastores G.M., Mehta A., Beck M., Gal A. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum. Mutat. 2005, 25(4):412.
33. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285(21):2743-2749.
34. Scionti I., Greco F., Ricci G., Govi M., Arashiro P., Vercelli L., Berardinelli A., Angelini C., Antonini G., Cao M., Di Muzio A., Moggio M., Morandi L., Ricci E., Rodolico C., Ruggiero L., Santoro L., Siciliano G., Tomelleri G., Trevisan C.P., Galluzzi G., Wright W., Zatz M., Tupler R. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. 2012, 90(4):628-635.
35. Shabbeer J., Robinson M., Desnick R.J. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography. Hum. Mutat. 2005, 25(3):299-305.
36. Shi Q., Chen J., Pongmoragot J., Lanthier S., Saposnik G. Prevalence of Fabry disease in stroke patients-a systematic review and meta-analysis. J. Stroke Cerebrovasc. Dis. 2014, 23(5):985-992.
37. Tanislav C., Kaps M., Rolfs A., Böttcher T., Lackner K., Paschke E., Mascher H., Laue M., Blaes F. Frequency of Fabry disease in patients with small-fibre neuropathy of unknown aetiology: a pilot study. Eur. J. Neurol. 2011, 18:631-636.
38. Tawil R., Van Der Maarel S.M. Facioscapulohumeral muscular dystrophy. Muscle Nerve 2006, 34(1):1-15.
39. Topaloglu A.K., Ashley G.A., Tong B., Shabbeer J., Astrin K.H., Eng C.M., Desnick R.J. Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol. Med. 1999, 5(12):806-811.
40. Watanabe T., Hanawa H., Suzuki T., Jiao S., Yoshida K., Ogura M., Ohno Y., Hayashi Y., Ito M., Kashimura T., Obata H., Sato A., Ozawa T., Kodama M., Sakuraba H., Minamino T. A mutant mRNA expression in an endomyocardial biopsy sample obtained from a patient with a cardiac variant of Fabry disease caused by a novel acceptor splice site mutation in the invariant AG of intron 5 of the α-galactosidase A gene. Intern. Med. 2013, 52(7):777-780.
41. Wijmenga C., Hewitt J.E., Sandkuijl L.A., Clark L.N., Wright T.J., Dauwerse H.G., Gruter A.M., Hofker M.H., Moerer P., Williamson R., et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat. Genet. 1992, 2(1):26-30.
42. Yokoi T., Shinoda K., Ohno I., Kato K., Miyawaki T., Taniguchi N. A 3' splice site consensus sequence mutation in the intron 3 of the alpha-galactosidase A gene in a patient with Fabry disease. Jinrui Idengaku Zasshi 1991, 36(3):245-250.
43. Zhang X.K., Elbin C.S., Chuang W.L., Cooper S.K., Marashio C.A., Beauregard C., Keutzer J.M. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin. Chem. 2008, 54(10):1725-1728.